ENvue Medical, Inc.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the six months ended June 30, 2026, the Company issued an aggregate of 7,600 shares of Series H Preferred Stock to Alpha upon exercises of the Additional Investment Right under the July 2025 Purchase Agreement, on January 5, 2026, January 31, 2026, March 24, 2026, April 28, 2026, May 28, 2026 and June 29, 2026, for aggregate gross proceeds of $7,600, of which 3,700 shares for gross proceeds of $3,700 were issued during the three months ended June 30, 2026. During the same period, Alpha converted $7,719 of stated value of Series H Preferred Stock, together with $602 of accrued dividends, into 6,049,233 shares of Common Stock, of which $2,917 of stated value and $151 of accrued dividends converted into 3,448,738 shares of Common Stock during the three months ended June 30, 2026. The shares of Series H Preferred Stock were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder, and the shares of Common Stock issued upon conversion were issued in reliance on the exemption provided by Section 3(a)(9) of the Securities Act. Except as set forth above, there were no unregistered sales of equity securities during the quarter ended June 30, 2026 that were not previously reported in our Current Reports on Form 8-K filed with the SEC.